Philippe Hénon - Search Results

Year	Number of Results
2003	2
2008	1
2009	1
2011	1
2013	1
2015	1
2016	1
2018	1
2019	1
2020	1
2021	1
2022	1
2023	0

1

Key Success Factors for Regenerative Medicine in Acquired Heart Diseases.

Hénon P. Hénon P. Stem Cell Rev Rep. 2020 Jun;16(3):441-458. doi: 10.1007/s12015-020-09961-0. Stem Cell Rev Rep. 2020. PMID: 32297205 Free PMC article. Review.

2

Human embryonic or adult stem cells: an overview on ethics and perspectives for tissue engineering.

Henon PR. Henon PR. Adv Exp Med Biol. 2003;534:27-45. doi: 10.1007/978-1-4615-0063-6_3. Adv Exp Med Biol. 2003. PMID: 12903709 Review.

3

Industrialized GMP Production of CD34⁺ Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.

Hénon P, Kowalczyk M, Aries A, Vignon C, Trébuchet G, Lahlil R. Hénon P, et al. Stem Cell Rev Rep. 2022 Jun;18(5):1614-1626. doi: 10.1007/s12015-022-10373-5. Epub 2022 Apr 14. Stem Cell Rev Rep. 2022. PMID: 35420389 Free PMC article.

4

Differential Expression of the Tetraspanin CD9 in Normal and Leukemic Stem Cells.

Lahlil R, Scrofani M, Aries A, Hénon P, Drénou B. Lahlil R, et al. Among authors: henon p. Biology (Basel). 2021 Apr 8;10(4):312. doi: 10.3390/biology10040312. Biology (Basel). 2021. PMID: 33918035 Free PMC article.

5

VSELs Maintain their Pluripotency and Competence to Differentiate after Enhanced Ex Vivo Expansion.

Lahlil R, Scrofani M, Barbet R, Tancredi C, Aries A, Hénon P. Lahlil R, et al. Among authors: henon p. Stem Cell Rev Rep. 2018 Aug;14(4):510-524. doi: 10.1007/s12015-018-9821-1. Stem Cell Rev Rep. 2018. PMID: 29736843 Free PMC article.

6

Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy.

Schmitt C, Voegelin M, Marin A, Schmitt M, Schegg F, Hénon P, Guenot D, Tarnus C. Schmitt C, et al. Among authors: henon p. Bioorg Med Chem. 2013 Apr 1;21(7):2135-44. doi: 10.1016/j.bmc.2012.12.038. Epub 2013 Feb 9. Bioorg Med Chem. 2013. PMID: 23428964

7

Cell surface CD43 determination improves diagnostic precision in late B-cell diseases.

Jung G, Eisenmann JC, Thiébault S, Hénon P. Jung G, et al. Among authors: henon p. Br J Haematol. 2003 Feb;120(3):496-9. doi: 10.1046/j.1365-2141.2003.04071.x. Br J Haematol. 2003. PMID: 12580968

8

Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34⁺ Cells for Clinical Use After Myocardial Infarction.

Saucourt C, Vogt S, Merlin A, Valat C, Criquet A, Harmand L, Birebent B, Rouard H, Himmelspach C, Jeandidier É, Chartois-Leauté AG, Derenne S, Koehl L, Salem JE, Hulot JS, Tancredi C, Aries A, Judé S, Martel E, Richard S, Douay L, Hénon P. Saucourt C, et al. Among authors: henon p. Stem Cells Transl Med. 2019 Aug;8(8):822-832. doi: 10.1002/sctm.17-0277. Epub 2019 Apr 29. Stem Cells Transl Med. 2019. PMID: 31037857 Free PMC article.

9

Human Very Small Embryonic-Like Stem Cells Are Present in Normal Peripheral Blood of Young, Middle-Aged, and Aged Subjects.

Sovalat H, Scrofani M, Eidenschenk A, Hénon P. Sovalat H, et al. Among authors: henon p. Stem Cells Int. 2016;2016:7651645. doi: 10.1155/2016/7651645. Epub 2015 Nov 8. Stem Cells Int. 2016. PMID: 26633977 Free PMC article.

10

Identification and isolation from either adult human bone marrow or G-CSF-mobilized peripheral blood of CD34(+)/CD133(+)/CXCR4(+)/ Lin(-)CD45(-) cells, featuring morphological, molecular, and phenotypic characteristics of very small embryonic-like (VSEL) stem cells.

Sovalat H, Scrofani M, Eidenschenk A, Pasquet S, Rimelen V, Hénon P. Sovalat H, et al. Among authors: henon p. Exp Hematol. 2011 Apr;39(4):495-505. doi: 10.1016/j.exphem.2011.01.003. Epub 2011 Jan 14. Exp Hematol. 2011. PMID: 21238532 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results